CONTINUATION PAGE: STAY WITHIN MARGINS INDICATED 
Principal Investigator/Program Director (Last, first, middle): Freedutari/ R. S./ 
M.D., Ph.D. 
SELECTED PUBUCATIONS (from a total of 101) 
Freedman RS, Saul PB, Edwards CL, Jolles CJ, Gershenson DM, Jones LA, Atkinson EN, Dana WJ. 
Ethinyl estradiol and medroxyprogesterone acetate in patients with epithelial ovarian carcinoma; A 
Phase II Study. Cancer Treat Rep 70:369-373, 1986. 
Savage HE, Rossen RD, Hersh EM, Freedman RS., Bowen JM, Plager G. Antibody development to 
viral and allogeneic tumor cell associated antigens in patients with malignant melanoma and 
ovarian carcinoma treated with lysates of virus infected tumor cells. Cancer Res 467:2127-2133 
1986. 
Freedman RS, Edwards CL, Bowen JM, Lotzov5 E, Katz R, Lewis E, Atkinson N, Carsetti R. Viral 
oncolysates in patients with advanced ovarian cancer. Gynecol Oncol 29:337-347, 1988. 
LotzovS E, Savary CA, Freedman RS, Edwards CL, and Wharton JT. Recombinant IL-2 activated NK 
cells mediate LAK activity against ovarian cancer. Int J Cancer 42:225-231, 1988. 
Freedman RS, Bowen J, Delclos L, Atkinson E, Lotzova E, Wharton JT, Edwards CE, Scott W, Patenia 
B, Bass S. Randomized comparison of viral oncolysate plus radiation and radiation alone in 
uterine cervix carcinoma. Am J Clin Oncol (CCT) 12(3): 244-250, 1989. 
loannides CG, Platsoucas CD, Bowen JM, Wharton JT, and Freedman RS. Increased ovarian tumor 
celi surface reacting antibodies in patients with ovarian adenocarcinoma after viral oncolysate 
therapy. Anticancer Res. 9:81-86,1989. 
Gershenson DM, Wharton JT, Copeland U, Stringer CA, Edwards CL, Kavanagh JJ, and Freedman 
RS. Treatment of advanced epitheliai ovarian cancer with cisplatin and cyclophosphamide. 
Gynecol Oncol 32:336-341, 1989. 
loannides CG, Freedman RS, and Platsoucas CD. 0KT4 monoclonal antibody-induced activation of an 
autoreactive T cell clone. Cellular Immunol 123:244-252, 1989. 
Freedman RS, Kouttab NM, Bowen JM, Edwards CL and Katz RL. Lymphokine activity in maiignant 
effusion after intracavitary virai oncolysates. Lymphokine Res 8:2:115-122, 1989. 
Sandies LG, Freedman RS, Raber MN, Kavanagh J, Edwards CL, Scott W, and Wharton JT. Phase I 
evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies. 
Gynecoi Oncol. 39:139-145, 1990. 
Freedman RS, loannides CG, Tomasovic B, Patenia R, Zhang H-Z, Liang J, and Edwards CL. 
Development of a cell surface reacting human monoclonal antibody agent in ovarian carcinoma. 
Hybridoma 10:21-33,1991. 
loannides CG, Freedman RS, Rashed S, Platsoucas CD, and Kim Y-P. Cytotoxic T cell clones isolated 
from ovarian tumor infiltrating lymphocytes recognize multiple antigenic epitopes on autologous 
tumor cells. J Immunol, 146:1700-1707, 1991. 
loannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL and Freedman RS. Tumor 
cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51:4257-4265, 1991. 
loannides CG, Freedman RS, Patenia R, Bowen JM, Ward N, and O'Brian CA. Immunological effects 
of tumor vaccines: III. Influenza virus oncolysates inhibit the TPA induced activation of peripheral 
blood mononuclear cells. In Wvo 5:1-6, 1991. 
loannides CG^- Rashed S, Fisk B, Fan D, Itoh K, Freedman RS. Lymphocytes infiltrating ovarian 
malignant ascites: Modulation of IL-2 induced proliferation by IL-4 and of selective increase in 
CD8+ T cells by TNF-a. Lymphokine Cytokine Res 10:307-315, 1991 . 
loannides CG, and Freedman RS. T cell responses to ovarian tumor vaccines. Internat Rev Immunol 
7:349-364, 1991. 
Freedman RS, loannides CG, Mathioudakis G, Platsoucas CD. Novel Immunologic strategies in 
ovarian carcinoma. Am J Obstet Gyn 167:1470-1478, 1992. 
Kooi S, Freedman RS, Rodgriguez-Villanueva J, and Platsoucas CD. Cytokine production by T-cell 
lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: Tumor 
-specific immune responses and inhibition of antigen-independent cytokine production by ovarian 
tumor cells. Lymphokine Cytokine Res 12:429-437, 1993. 
Freedman RS, Tomasovic B, Templin S, Atkinson EN, Kudelka A, Edwards CL, Platsoucas CD. Large 
scale expansion in IL-2 of tumor infiltrating lymphocytes from patients with ovarian carcinoma for 
adoptive immunotherapy. J Immunol Methods ‘\67:‘\A5-^60, 1994.. 
Freedman RS, Edwards CL, Kavanagh JJ, Kudelka A, Katz RL, Carrasco CH, Atkinson EN, Stcott W, 
Tomasovic B, Templin S, Platsoucas CD. Intraperitoneal adoptive immunotherapy of ovarian 
carcinoma with tumor infiltrating lymphocytes, (in preparation) 1994. 
Platsoucas CD, and Freedman RS. Tumor infiltrating lymphocytes in gene therapy, (in press), 1993. 
Freedman RS, Bowen JM, Delclos L, Edwards CL, Wallace S, Atkinson EN, loannides CG, Kasi LP, 
Scott W, Patenia R. Active intralymphatic Immunotherapy of uterine cervical carcinoma with uirpi 
oncolysate. A pi lot study. Int J Gynecol Ca ncer 4:1 01 -1 1 0, 1994. 
(4041 Recombinant DNA Research, Volume 19 
